Company Shares of Pacific Biosciences of California (NASDAQ:PACB) Rally 7.11%

Pacific Biosciences of California (NASDAQ:PACB) has been under a strong bear grip, hence the stock is down -22.49% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.76% in the past 1 week. The stock has risen by 7.11% in the past week indicating that the buyers are active at lower levels, but the stock is down -21.23% in the past 4 weeks.

The company shares have rallied 37.66% from its 1 Year high price. On Dec 31, 2015, the shares registered one year high at $14.00 and the one year low was seen on Sep 30, 2015. The 50-Day Moving Average price is $8.74 and the 200 Day Moving Average price is recorded at $9.58.

The stock has recorded a 20-day Moving Average of 9.85% and the 50-Day Moving Average is 15.63%.


Pacific Biosciences of California (NASDAQ:PACB): stock turned positive on Friday. Though the stock opened at $7.37, the bulls momentum made the stock top out at $7.59 level for the day. The stock recorded a low of $7.24 and closed the trading day at $7.53, in the green by 2.73%. The total traded volume for the day was 1,250,511. The stock had closed at $7.33 in the previous days trading.

In an insider trading activity,The officer (SVP, Research & Development) of Pacific Biosciences Of California, Inc., Phillips James Michael sold 20,000 shares at $10.29 on April 25, 2016. The Insider selling transaction had a total value worth of $205,800. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.